Introduction {#s0005}
============

Paracetamol (acetaminophen) has been extensively studied as analgesic for pain relief in many clinical settings but its mechanism of action still is under considerable debate. Paracetamol crosses the blood brain barrier and many reports indicate that paracetamol exerts its antinociceptive activity not only peripherally, but also within the central nervous system (CNS) ([@b0060]). In addition, paracetamol also exhibits antinociceptive effects in tests that are reputed to be sensitive only to central analgesics, as hot-plate test and tail-flick test ([@b0130], [@b0165]), and intracerebroventricular or intrathecal administration of paracetamol have also been shown to provide antinociception ([@b0010], [@b0135]). Paracetamol has been shown to act as a selective COX-2 inhibitor in the CNS, where the concentration of tissue peroxides is low unlike at sites of inflammation ([@b0095], [@b0105]). Also, the analgesic effects of paracetamol are attenuated by drugs that act via inhibition of serotonergic, opioid and cannabinoid systems ([@b0125], [@b0190]) suggesting that a number of neurotransmitter system may be involved in the central antinociceptive mechanism of paracetamol, in particular, serotonergic pathways. In support of this, different studies have shown that action of paracetamol is significantly reduced when lesions are produced in the serotonergic pathway or by inhibiting synthesis of serotonin (5-HT) in animal models ([@b0160], [@b0185]). Conversely, paracetamol treatment induces a significant increase in 5-HT levels in the brainsterm ([@b0065]). Another hypothesis that has surfaced is that the analgesic action of systemically administered paracetamol could be attributed to spinal 5-HT (5-HT~3~ and 5-HT~7~) receptors mediated the enhanced neurotransmitter release in the descending serotonergic pathway, which is responsible for modulation of pain at the spinal level ([@b0075]). However, other studies report a serotonergic facilitatory modulation onto the spinal cord through 5-HT~3~ in different pain models ([@b0020], [@b0175]).

We have previously shown that the antinociceptive effect of tramadol, an analgesic that, like paracetamol is able to increase serotonin levels within CNS, is potentiated or antagonized respectively by a 5-HT~1A/B~ nonspecific receptor blockade or activation ([@b0155]). Moreover, it has been shown that the antinociceptive effect of clomipramine, 5-HT and NA re-uptake inhibitor, is also enhanced by the specific blockade of 5-HT~1A~ receptors ([@b0015]). In other study, we have shown that the selective blockade of the 5-HT~1A~ or 5-HT~1B~ potentiate the antinociceptive effect of paracetamol in the hot plate test, while this antinociceptive effect of paracetamol can antagonized by specific agonist of these autoreceptors, 5-HT~1A~ and 5-HT~1B~ ([@b0145]). The hot plate test is one of the most commonly used tests of analgesic measure of analgesic drugs that act at the level of spine and higher centres ([@b0195]). As both central as well as peripheral mechanisms of paracetamol has been proposed, in the current study we employed the formalin test to assess the effect of blockade or activation of 5-HT~1A~ or 5-HT~1B~ receptors, by specific antagonist or agonist, on antinociceptive action of paracetamol in rats.

Material and methods {#s0010}
====================

Animals {#s0015}
-------

Experiments were carried out on adult male Wistar rats, 200--250 body weight, under standard laboratory conditions (22 °C, 12 h light/dark cycle, lights on at 08:00 AM, food and water *ad libitum*) (n = 8--11/group). All procedures and animal handling were in accordance with the guidelines of European Commission's directive (2010/63/EC) and Spanish Law (RD 53/2013) regulating animal research, and all the experimental protocols were approved by the Committee for Animal Experimentation at the University of Cadiz (Spain).

Drugs {#s0020}
-----

The following drugs were used: propacetamol (provided by UPSA Laboratories Spain, Bristol-Myers-Squibb Group, Madrid, Spain), N-\[2-\[4-(2-Methoxyphenyl)-1-piperazinyl\]ethyl\]-N-2-pyridinylcyclohexanecarboxamide (WAY 100,635) (Sigma, St Louis, MO, USA), N-\[3-\[3-(Dimethylamino)ethoxy\]-4-methoxyphenyl\]-2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)-\[1,1′ biphenyl\]-4-carboxamide (SB 216,641) (Tocris, Bristol, U.K.), 8-Hydroxy-2-(di-*n*-propylamine) tetralin (8-OH-DPAT) (Sigma, St Louis, MO, USA) and 1,4-Dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5H-pyrrol\[3,2-b\]pyridin-5-one (CP 93,129) (Tocris, Bristol, U.K.). Control animals received saline (NaCl 0.9%).

Propacetamol is a prodrug which is completely hydrolysed to paracetamol by plasma esterases within 7 min after intravenous injection (2 g of propacetamol are equivalent to 1 g of paracetamol ([@b0025]). Therefore, 2 g of propacetamol was dissolved in saline and intraperitoneally administered at equivalent dosis of paracetamol of 125, 250, 500 and 1000 mg/kg at a volume injection of 1 ml/kg body weight. The others drugs were dissolved in saline and subcutaneously administered in a volume injection of 1 ml/kg body weight. WAY 100,635 and SB 216,641 were administered at dose of 0.8 mg/kg. 8-OH-DPAT and CP 93,129 were administered at dose of 0.125 mg/kg. The doses of WAY 100,635, SB 216,641 and 8-OH-DPAT were chosen based on published data ([@b0150], [@b0155]). The doses of CP 93,129 were chosen on the basis of previous studies performed in our laboratory (data not published).

Formalin test {#s0025}
-------------

The formalin test was performed as described Dubbuison and Dennis ([@b0080]). Before testing, animals were placed individually in standard cages for 15 min for three days, after these three adaptation periods, the formalin test was carried out. 50 μL of 5% formalin solution was injected subcutaneously into the dorsal surface of the right hind paw. Pain behavior was monitored for a period of 60 min; the number of flinches/shakes of the injected paw was summed at 5-min intervals starting at time 0. Two phases of spontaneous flinches behavior were observed: phase 1 began immediately after formalin injection to 10 min thereafter and phase 2 began at time 10 min. A maximum response was observed around 20--45 min after the formalin injection.

### Experimental protocol {#s0030}

First, three adaption sessions were carried out for each animal before testing. After this, paracetamol or saline was intraperitoneally administered, and 15 min later, the antagonist (WAY 100,635 or SB 216,641) or agonist (8-OH-DPAT or CP 93,129), of 5-HT~1A~ or 5-HT~1B~ receptors respectively, or saline was subcutaneously injected. Formalin was administered 30 min after paracetamol administration and immediately the animal was placed in individual behavioural cage, the test was recorded for 60 min.

Statistical analysis {#s0035}
--------------------

Results were expressed as mean ± SEM of the number of flinches/shakes of the phase 1 and 2 of the formalin test. The data obtained from the formalin test were statistically analyzed using two-way ANOVA. The factors of variation were paracetamol treatment and serotonin antagonist or agonist treatment. Subsequent one-way ANOVA was performed followed by Student-Newman-Keuls′ test, a value of *p* \< 0.05 was considered to be significant.

Results {#s0040}
=======

Antinociceptive effect of paracetamol in formalin test {#s0045}
------------------------------------------------------

The antinociceptive effect of paracetamol was evaluated in the formalin test in rats. One-way ANOVA showed a significant effect of treatment in both phases of the formalin test (Phase 1: F~4,34~ = 10.88, *P* \< 0.001; phase 2: F~4,34~ = 19.21, *P* \< 0.001). Paracetamol induced an increase in pain response latency in a dose-related manner in both phases of the formalin test ([Fig. 1](#f0005){ref-type="fig"}). In phase 1, paracetamol 250 mg/kg, but not 125 mg/kg, induced a non significant decrease of the number of flinches. Whereas, paracetamol 500 mg/kg and 1000 mg/kg induced a significant decreased of the number of flinches when compare to saline treated group. Also, dose of 1000 mg/kg induced significant decreased of the number of flinches compared to the doses of 125 and 250 mg/kg of paracetamol. In phase 2, paracetamol 125 mg/kg induced a non significant decreased of the number of flinches. However, paracetamol 250, 500 and 1000 mg/kg induced a significant decreased of the number of flinches compared to saline treated group, also, the decrease of number of flinches induced by paracetamol 500 and 1000 mg/kg was significant compared to paracetamol 125 and 250 mg/kg.Fig. 1Antinociceptive effect of paracetamol in formalin test. Different doses of paracetamol (125, 250, 500 and 1000 mg/kg) or saline were administered 30 min before of formalin test. Two phases of spontaneous flinches/shakes behavior were observed over the 60 min test period. Error bars represent the SEM of 7--8 animals/group. \* p \< 0.05 vs saline, \# p \< 0.05 vs PARA 125 and 250 mg/kg as assessed by one-way ANOVA followed by a Newman-Keuls post-test.

Therefore, paracetamol exert an antinociceptive effect in a dose-dependent manner in the formalin test.

We chose the doses of 125 and 250 mg/kg of paracetamol, with weak analgesic effect, to examine its association with specific antagonist of the serotonin receptors subtypes, 5-HT~1A~ and 5-HT~1B~. The doses of 500 and 1000 mg/kg of paracetamol, with strong analgesic effect, were chosen to test its combination with specific agonists of the 5-HT~1A~ and 5-HT~1B~ receptors.

Involvement of 5-HT~1A~ receptors in the antinociceptive effect of paracetamol {#s0050}
------------------------------------------------------------------------------

### Effect of 5-HT~1A~ antagonist on antinociceptive effect of paracetamol {#s0055}

The effect of WAY 100,635 0.8 mg/kg (selective 5-HT~1A~ antagonist) on the antinociceptive effect of paracetamol 125 mg/kg (a non effective analgesic dose) and 250 mg/kg (a weak antinociceptive dose) was evaluated using the formalin test. A Two-way ANOVA revealed a significant effect of paracetamol (Phase 1: F~2,48~ = 6.43, *P* \< 0.004; Phase 2: F~2,48~ = 25.37, *P* \< 0.0001) and WAY 100,635 (Phase 1: F~1,48~ = 10.10, *P* \< 0.003; Phase 2: F~1,48~ = 13.05, *P* \< 0.001). No significant effect was observed in the interaction of both treatments (Phase 1: F~2,48~ = 0.83, N.S.; Phase 2: F~2,48~ = 0.37, N.S.).

When the analgesic effect of a non effective analgesic dose of paracetamol (125 mg/kg) was measured, one-way ANOVA showed a significant effect of the treatment of 125 mg/kg of paracetamol in phase 2 (F~3,30~ = 9.57, *P* \< 0.0001), although the treatment was non significant in phase 1 (F~3,30~ = 2.46, N.S.) of the formalin test. Likewise, the number of flinches in paracetamol-WAY 100,635 treated animals was modified ([Fig. 2](#f0010){ref-type="fig"}A). This decreased of the number of flinches induced by WAY 100,635 in rats receiving paracetamol 125 mg/kg was statistically significant compared to saline treated animals in both phases. WAY 100,635 had no effect in saline-treated animals.Fig. 2Effect of WAY 100,635 (0.8 mg/kg), 5-HT~1A~ antagonist, on antinociceptive effect of paracetamol (125 and 250 mg/kg; *A and B respectively*). WAY100635 was administered 15 min after paracetamol administration. Formalin test was performed 30 min after of paracetamol administration. Two phases of spontaneous flinches/shakes behavior were observed over the 60 min test period. Error bars represent the SEM of 8--9 animals/group. \* p \< 0.05 vs saline, \# p \< 0.05 vs PARA 250 mg/kg as assessed by one-way ANOVA followed by a Newman-Keuls post-test.

Similarly, the analgesic effect of paracetamol was measured with a weak antinociceptive dose. In one-way ANOVA of 250 mg/kg of paracetamol revealed a significant effect of the treatment in both phases of the formalin test (Phase 1: F~3,30~ = 8.39, *P* \< 0.0001; Phase 2: F~3,30~ = 27.34; *P* \< 0.0001) ([Fig. 2](#f0010){ref-type="fig"}B). Also it could be observed as WAY 100,635 increased the antinociceptive effect of paracetamol, it induced a significant decrease of the number of flinches in both phases respect to paracetamol 250 mg/kg treated animals.

These results show that 5-HT~1A~ antagonist, WAY 100,635, increase the antinociceptive effect of paracetamol and, consequently, 5-HT~1A~ receptors maybe involved in the antinociceptive mechanism of paracetamol.

### Effect of 5-HT~1A~ agonist on antinociceptive effect of paracetamol {#s0060}

The effect of 8-OH-DPAT 0.125 mg/kg (a selective 5-HT~1A~ agonist) on the antinociceptive effect of paracetamol 500 and 1000 mg/kg was evaluated. Two-way ANOVA showed a significant effect of paracetamol (Phase 1: F~2,48~ = 16.75, *P* \< 0.0001; Phase 2: F~2,48~ = 113.75, *P* \< 0.0001) and the interaction of both treatment (Phase 1: F~2,48~ = 4.26, *P* \< 0.021; Phase 2: F~2,48~ = 3.57, *P* \< 0.037) in phases 1 and 2 of the formalin test. But no significant effect of 8-OH-DPAT was observed in both phases of the formalin test (Phase 1: F~1,48~=, N.S.; Phase 2: F~1,48~ = 3.47, N.S.).

One-way ANOVA showed a significant effect of 8-OH-DPAT on the antinociceptive effect of 500 mg/kg of paracetamol in both phases (Phase 1: F~3,31~ = 5.43, *P* \< 0.005.; Phase 2: F~3,31~ = 36.17, P \< 0.0001) of the formalin test ([Fig. 3](#f0015){ref-type="fig"}A). In phase 1, 8-OH-DPAT induced a non significant increase of the number of flinches in paracetamol-treated animals, however produced a significant increase in animals receiving paracetamol in the second phase. 8-OH-DPAT had no effect in saline treated animals ([Fig. 3](#f0015){ref-type="fig"}A).Fig. 3Effect of 8-OH-DPAT (0.125 mg/kg), 5-HT~1A~ agonist, on antinociceptive effect of paracetamol (500 mg/kg and 1 g/kg; *A and B respectively*). 8-OH-DPAT was administered 15 min after paracetamol administration. Formalin test was performed 30 min after of paracetamol administration. Two phases of spontaneous flinches/shakes behavior were observed over the 60 min test period. Error bars represent the SEM of 8--9 animals/group. \* p \< 0.05 vs saline and DPAT, \# p \< 0.05 vs PARA 500 mg/kg and 1 g/kg as assessed by one-way ANOVA followed by a Newman-Keuls post-test.

Similarly, experiments were repeated with 1000 mg/kg of paracetamol and one-way ANOVA revealed a significant effect of 8-OH-DPAT on the antinociceptive effect of paracetamol in both phases of the formalin test (Phase 1: F~3,31~ = 9.41, *P* \< 0.0001; Phase 2: F~3,31~ = 49.53; *P* \< 0.0001) ([Fig. 3](#f0015){ref-type="fig"}B). 8-OH-DPAT modified the antinociceptive effect of paracetamol, it induced a significant increase of the number of flinches in both phases in paracetamol 1000 mg/kg treated animals.

These results show that 5-HT~1A~ agonist, 8-OH-DPAT, decreased the antinociceptive effect of paracetamol suggesting the possible role of the 5-HT~1A~ receptors in the antinociceptive mechanism of paracetamol.

Involvement of 5-HT~1B~ receptors in the antinociceptive effect of paracetamol {#s0065}
------------------------------------------------------------------------------

### Effect of 5-HT~1B~ antagonist on antinociceptive effect of paracetamol {#s0070}

The effect of SB 216,641 0.8 mg/kg (a selective 5-HT~1B~ antagonist) on the antinociceptive effect of paracetamol 125 mg/kg (a non effective dose) and 250 mg/kg (a weak antinociceptive dose) was tested. Two-way ANOVA revealed a significant effect of paracetamol (Phase 1: F~2,56~ = 9.09, *P* \< 0.0001; Phase 2: F~2,56~ = 16.54, *P* \< 0.0001) and no significant effect of SB 216,641 (Phase 1: F~1,56~ = 2.42, N.S.; Phase 2: F~1,56~ = 2.33, N.S.) was observed, nor any interactions between both treatments (Phase 1: F~2,48~ = 0.83, N.S.; Phase 2: F~2,48~ = 0.37, N.S.).

When the analgesic effect of 125 mg/kg of paracetamol with a selective 5-HT~1B~ antagonist SB 216,641 was measured, one-way ANOVA showed a non-significant effect of SB 216,641 on the antinociceptive effect of paracetamol in both phases (Phase 1: F~3,37~ = 0.41, N.S.; Phase 2: F~3,37~ = 2.25, N.S.) of the formalin test. SB 216,641 induced a non-significant increased of the antinociceptive effect in paracetamol treated animals ([Fig. 4](#f0020){ref-type="fig"}A). SB 216,641 had no effect in saline treated animals.Fig. 4Effect of SB 216,641 (0.8 mg/kg), 5-HT~1B~ antagonist, on antinociceptive effect of paracetamol (125 and 250 mg/kg; *A and B respectively*). SB 216,641 was administered 15 min after paracetamol administration. Formalin test was performed 30 min after of paracetamol administration. Two phases of spontaneous flinches/shakes behavior were observed over the 60 min test period. Error bars represent the SEM of 10--11 animals/group. \* p \< 0.05 vs saline and SB as assessed by one-way ANOVA followed by a Newman-Keuls post-test.

In the same manner experiments were repeated with 250 mg/kg of paracetamol and one-way ANOVA revealed a significant effect of SB 216,641 on the antinociceptive effect of paracetamol in both phases of the formalin test (Phase 1: F~3,37~ = 7.78, *P* \< 0.0001; Phase 2: F~3,37~ = 18.79; *P* \< 0.0001) ([Fig. 4](#f0020){ref-type="fig"}B). SB 216,641 modified the antinociceptive effect of paracetamol. It induced a non-significant decrease of the number of flinches in both phases in paracetamol 250 mg/kg treated animals.

According to results, SB 216,641 0.8 mg/kg, 5-HT~1B~ antagonist, not show a clear effect on the antinociceptive action of paracetamol.

### Effect of 5-HT~1B~ agonist on antinociceptive effect of paracetamol {#s0075}

The effect of CP 93,129 0.125 mg/kg (a selective 5-HT~1B~ agonist) on the antinociceptive effect of paracetamol 500 y 1000 mg/kg was examined. Two-way ANOVA revealed a significant effect of paracetamol (Phase 1: F~2,54~ = 61.97, *P* \< 0.0001; Phase 2: F~2,54~ = 196.49, *P* \< 0.0001) and no significant effect of CP 93,129 (Phase 1: F~1,54~ = 0.34, N.S.; Phase 2: F~1,54~ = 1.31, N.S.) was observed, nor any interactions between both treatments (Phase 1: F~2,54~ = 0.16, N.S.; Phase 2: F~2,54~ = 2.70, N.S.).

Antinociceptive effect of 500 mg/kg of paracetamol was studied and one-way ANOVA showed a significant effect in both phases (Phase 1: F~3,35~ = 17.57, *P* \< 0.005.; Phase 2: F~3,35~ = 60.04, P \< 0.0001) of the formalin test. CP 93,129 had no effect in saline treated animals and did not modify the antinociceptive effect produced by paracetamol in both phases of the formalin test ([Fig. 5](#f0025){ref-type="fig"}A).Fig. 5Effect of CP 93,129 (0.125 mg/kg), 5-HT~1B~ agonist, on antinociceptive effect of paracetamol (500 mg/kg and 1 g/kg; *A and B respectively*). CP 93,129 was administered 15 min after paracetamol administration. Formalin test was performed 30 min after of paracetamol administration. Two phases of spontaneous flinches/shakes behavior were observed over the 60 min test period. Error bars represent the SEM of 9--10 animals/group. \* p \< 0.05 vs saline and CP as assessed by one-way ANOVA followed by a Newman-Keuls post-test.

Similar results were observed with 1000 mg/kg of paracetamol, one-way ANOVA revealed that this dose had a significant antinociceptive effect in both phases of the formalin test (Phase 1: F~3,35~ = 28.37, *P* \< 0.0001; Phase 2: F~3,35~ = 76.74; *P* \< 0.0001) ([Fig. 5](#f0025){ref-type="fig"}B). CP 93,129 modified weakly the antinociceptive effect of paracetamol, but it induced a non-significant increase of the number of flinches in both phases in paracetamol treated animals.

In line with the above results, CP 93,129 0.125 mg/kg, 5-HT~1B~ agonist, not show a significant effect on the antinociceptive action of paracetamol.

Discussion {#s0080}
==========

In this study, we evaluated whether the 5-HT~1A~ and 5-HT~1B~ receptors are involved in the antinociceptive effect of paracetamol in the rat model of formalin-induced pain. Flinches were used to quantify formalin-induced behaviours since they provide a reliable correlation of pain in the awake, freely moving rat. The behavioural response to the injection of formalin is biphasic, with an acute phase followed by tonic phase. It has been suggested that the early phase is caused by a direct effect of formalin on nociceptors, whereas the second phase is due to an inflammatory process ([@b0100]). Therefore, the antinociceptive activity of paracetamol can be evaluated immediately after formalin injection. Our results showed a weak antinociceptive effect at doses of 125 and 250 mg/kg of paracetamol, and a strong analgesic effect at doses of 500 and 1000 mg/kg of paracetamol in both phases. In line with previously published data, our results confirmed that paracetamol is able to induce a dose-dependent antinociceptive activity in the formalin test in rat ([@b0075], [@b0085]).

To study whether the 5-HT~1A~ and 5-HT~1B~ receptors are involved in the antinociceptive effect of paracetamol, we evaluated if the blockade of the 5-HT~1A~ or 5-HT~1B~ autoreceptors by different antagonists (WAY 100,635 and SB 216,641, respectively) can potentiate the antinociceptive effect of paracetamol and, in contrast, the activation of the 5-HT~1A~ or 5-HT~1B~ by different agonists (8-OH-DPAT and CP 93,129, respectively) reduced the antinociceptive effect induced by paracetamol. Our data clearly show that WAY 100,635, selective 5-HT~1A~ antagonist, potentiates the antinociceptive effect of paracetamol in the formalin test. While 8-OH-DPAT, selective 5-HT~1A~ agonist, reduced its analgesic effect in the same test. However, our results not show a clear effect on the antinociceptive effect of paracetamol when is administered SB 216,641, selective 5-HT~1B~ antagonist, or CP 93,129, selective 5-HT~1B~ agonist.

The 5-HT~1A~ receptors have a somatodendritic location on 5-HT neurons of the midbrain raphe nuclei (autoreceptors) and on neurons postsynaptic to 5-HT nerve terminals, mainly in cortico-limbic areas that exerts a pronounced inhibitory influence upon the release of 5-HT throughout the CNS. Also, 5-HT~1A~ can be localised at the spinal cord, a diversity of analgesiometric paradigms has been employed and numerous behavioural studies have reported hyperalgesia upon spinal administration ([@b0005], [@b0030]). Stimulation of 5-HT~1A~ receptors also attenuates induction of antinociception by the antidepressant, clomipramine ([@b0015]). While some authors ([@b0035], [@b0055]) have demonstrated that a 5-HT~1A~ agonist, F13640, induced central analgesia in different analgesimetric test. Our results showed that the 5-HT~1A~ antagonist, WAY 100,635, induced an increase of antinociceptive effect of paracetamol in the formalin test at a low dose. These results are supported by different studies showing that alprenolol and WAY 100,635 induced antinociception in the writhing test mice ([@b0115], [@b0120]). Also, other study show paracetamol or venlafaxine with WAY 100,635 led to a significant antinociceptive effect ([@b0045]). A recent study, show the role of 5-HT~1A~ in the antinociceptive effect of paracetamol, but suggest that spinal 5-HT~7~ receptors are involved in a central antinociceptive and antihyperalgesic effect of paracetamol ([@b0075]). However, these results are conflicting, because some studies have shown that 5-HT~1A~ agonists induced antinociception. For instance, the antinociceptive effect of several 5-HT~1A~ agonist, as 8-OH-DPAT, has been demonstrated in the formalin test ([@b0090]) as well as the antinociceptive effect of buspirone increased the licking latency in the hot-plate test in mice ([@b0110]). These data seem to indicate that the results obtained in the experiments depends on the nature of the noxious stimuli and, consequently, to the nature of the afferent fibre involved and the administration route of the drug, thus, the serotonergic system pharmacologic is very complex in controlling nociceptive pathways.

Regarding the 5-HT~1B~ receptors, they act as terminal receptors and are involved in the presynaptic regulation of the release of 5-HT. But at spinal level these receptors are principally situated post-synaptically ([@b0170]). The ability of autoreceptors to regulate extracellular levels of 5-HT during release has made them the focus of much interest. Our results show that SB 216,641, selective 5-HT~1B~ antagonist, modified weakly the antinociceptive effect of paracetamol and CP 93,129, selective 5-HT~1B~ agonist, not produce a clear effect in the antinociceptive effect of paracetamol. In our study, CP 93,129 was used to a doses of 0.125 mg/kg, however, there are studies that show that CP 93,129 at 0.250 mg/kg or 2 mg/kg doses s.c., decreased the antinociceptive effect of paracetamol in the hot plate-test ([@b0145], [@b0160]). Therefore, higher doses of CP 93,129 could have an effect on the antinociceptive effect of paracetamol in the formalin test.

Moreover, many data indicate that locomotion may influence nociception, but the changes have not always been well elucidated ([@b0100]). In this line, it would be interesting to evaluate the spontaneous motor activity after treatment with the drugs used both alone or in combination.

As previously mentioned, it is well-known that the descending serotonergic pathway origins at supraspinal sources. The predominant proportion of serotonergic neurons arises from the nucleus raphe magnus, although, a modest sources of serotonergic neurons from dorsal raphe nucleus innervates the spinal cord as well ([@b0200]). Traditionally, actions of 5-HT in the descending serotonergic pathway have been considered to suppressed the nociceptive transmission ([@b0040]). Nevertheless, opposite actions (pronociceptive or antinociceptive) of 5-HT have been described depending on the 5-HT receptor and localisation of the specific 5-HT receptor types. Thus, activation of the 5-HT~1A~, 5-HT~1B~, 5-HT~1D~ and 5-HT~7~ receptors tends to be antinociceptive, whereas the 5-HT~2A~ and 5-HT~3~ receptor tend to promote nociception ([@b0140], [@b0180]). Antinociception in mice produced by rostroventromedial medulla morphine was blocked by spinal 5-HT~7~ antagonist and hyperalgesia produced by rostroventromedial medulla cholecystokinin was blocked by a spinal 5-HT~3~ antagonist ([@b0070]). In other studies in mice, systemic 5-HT~7~ agonists blocked hyperalgesia, whereas 5-HT~7~ antagonists elicited enhanced pain ([@b0050]). In this regard, antinociceptive or pronociceptive mechanism can be generated as result of the activation of the descending serotonergic pathway indicating an important serotonergic role for bidirectional pain modulation.

Conclusion {#s0085}
----------

In conclusion, the results of this study suggest that the antinociceptive effect of paracetamol in the formalin test can be enhanced mainly by antagonist of the 5-HT~1A~ receptors, and, perhaps, by antagonist compounds of the 5-HT~1B~ receptors. Consequently, these receptors have a role in the analgesic effect of paracetamol. Thus, this study provides a possible and a promising pharmacological combination for the development of a new analgesic strategy.
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